ServiziMenu principale

<< Torna a "Tutti gli studi"

Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines - Style Trial

Studio Clinico

Patologia: Altre neoplasie

Osservazionale-Sperimentale: Sperimentale

Monocentrico-Multicentrico: Monocentrico

Randomizzato: No

Fase di studio: II

Richiesta mandatoria di tessuto: 

Linee di trattamento: Seconda linea, Terza/N linea

Criteri di inclusione: 

- Signed and dated IRB (Independent Review Board)/IEC (Independent Ethics Committee)-approved Informed Consent
- Histological diagnosis of invasive recurrent or metastatic type B3 thymoma or thymic carcinoma. In case of presence of both histologies it will be classified based on the predominantly part. B2 thymoma with areas of B3 thymoma are eligible.
- Patients must have had at least one prior platinum-containing chemotherapy regimen. There is no limit to the number of prior chemotherapy regimens or targeted agents received. Progressive disease should have been documented before entry into the study
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured according with RECIST 1.1 criteria
- Availability of archival tissue (paraffine block or at least 10 unstained slides)
- Patients must have recovered from toxicity related to prior therapy to at least grade 1 (defined by v.CTCAE 4.0)
- Patients must not have had major surgery, radiation therapy, chemotherapy, biologic therapy (including any investigational agents), or hormonal therapy (other than replacement), within 4 weeks prior to entering the study
- Age > 18 years
- Life expectancy > 3 months
- Performance status (ECOG) ≤ 2
- Negative pregnancy test (if female in reproductive years)
- Patients must have adequate organ and marrow function (as defined below). Patients must have returned to baseline or grade 1 from any acute toxicity related to prior therapy:
    - Absolute neutrophil count ≥ 1,500/mm
    - Hemoglobin ≥ 9 g/dL
    - Platelets ≥ 100,000/mm
    - Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) , except for patients affected by Gilbert's syndrome
    - AST(SGOT) (aspartate aminotransferase) /ALT(SGPT) (alanine transaminase) ≤ 3 x institutional ULN (5x if LFT (liver function test) elevations due to liver metastases)
    - Creatinine ≤ 1.5 x institutional ULN
- Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception before study entry, for all the duration of the study and for at least 8 weeks after the last dose of investigational drug (30 days for an ovarian cycle turnover plus the time required for the active metabolite of sunitinib to undergo five half-lives).
- Males who are sexually active with WOCBP must agree to follow instructions for method(s) of before study entry, for all the duration of the study and for at least 16 weeks after the last dose of investigational drug (90 days for sperm turnover plus the time required for the active metabolite of sunitinib to undergo five half-lives).

Criteri di esclusione: 

- Untreated CNS metastases. Patients with treated brain metastases are eligible if they are clinically stable with regard to neurologic function, off steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, and stereotactic radiosurgery) ending at least 2 weeks prior to start of treatment, or after surgical resection performed at least 28 days prior to start of treatment. The patient may have no evidence of Grade ≥1 CNS haemorrhage based on pre-treatment Magnetic Resonance Imaging (MRI) or IV contrast CT scan (performed within 28 days before start of treatment)
- Major surgery, other than diagnostic surgery, within 4 weeks prior to treatment
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
- Pregnant or breast feeding women
- Previous (within the last 5 years) or current malignancies at other sites, except for adequately treated basal cell or squamous cell skin cancer or in situ carcinoma of the cervix uteri
- Current enrollment in or participation in another therapeutic clinical trial within 4 weeks before treatment start.
- Patients with uncontrolled or significant cardiovascular disease (AMI within 12 months, unstable angina within 6 months, NYHA (New York Heart Association) Class III, IV Congestive heart failure or left ventricular ejection fraction below local institutional lower limit of normal or below 45%
- Ongoing symptomatic cardiac dysrhythmias, uncontrolled atrial fibrillation, or prolongation of the Fridericia corrected QT (QTcF) interval defined as > 450 msec for males and > 470 msec for females, where QTcF = QT/3√RR
- Poorly controlled hypertension
- History of cerebrovascular accident including transient ischemic attack within the past 12 months.
- History of deep vein thrombosis (DVT) unless adequately treated with low molecular weight heparin
- History of pulmonary embolism within the past 6 months unless stable, asymptomatic, and treated with low molecular weight heparin for at least 6 weeks.
- Evidence of active bleeding or bleeding susceptibility; or medically significant hemorrhage within prior 30 days.
- Receiving concomitant CYP3A4 inducers or strong CYP3A4 inhibitors
- Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of sunitinib
- Known HIV infection

Schema di trattamento: 

Sunitinib orally administered at 50 mg once daily for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks

Trattamento sperimentale: 

Sunitinib

Trattamento di controllo: 

NA

Obiettivi primari dello studio: 

Activity of Sunitinib [ Time Frame: 4 years ]
Best tumour response (Complete Response + Partial Response)

Centri partecipanti

Nord Italia

IRCCS Istituto Nazionale dei Tumori
Via Venezian 1 - 20133 Milano - MI

Riferimento: Dr.ssa Marina Chiara Garassino
Telefono: 0223903813
Email: marina.garassino@istitutotumori.mi.it

Informazioni Generali

Protocollo

Numero di iscrizione a registro: NCT03449173

Data di inserimento: 16.04.2019

Promotore

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

CRO

/

Principal Investigator ITALIA

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Riferimento: Dr.ssa Marina Chiara Garassino

Telefono: 0223903813

Email: marina.garassino@istitutotumori.mi.it

Localita: Milano

 

<< Torna a "Tutti gli studi"